<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01983358</url>
  </required_header>
  <id_info>
    <org_study_id>JP-NC-P1-13</org_study_id>
    <nct_id>NCT01983358</nct_id>
  </id_info>
  <brief_title>The Evaluation of Safety, Tolerability and Pharmacokinetics of Stroke Targeting Drug in Healthy Volunteers</brief_title>
  <acronym>JPI-289</acronym>
  <official_title>A Phase I Clinical Study, Randomized, Double-blind, Placebo-controlled,Single Dose, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of JPI-289 in Healthy Male Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeil Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jeil Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study in to evaluate safety, tolerability, pharmacokinetics of JPI-289 in
      healthy male subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      tPA treatment should be used within 3 hours after stroke onset for treating efficacy, but
      JPI-289 treatment(PARP-1 inhibitor) showed treating efficacy more than 10 hours after stroke
      onset. PARP-1 inhibitor add-on therapy of tPA will be very useful to prevent social, economic
      loss from physical, and mental disable by stroke.

      This clinical trial progresses to explore safety, tolerability,
      pharmacokinetic/pharmacodynamic properties of JPI-289 by single dose escalation(7cohort).
      Investigational product medication of each level within 4 weeks evaluate safety and
      tolerability of patient through Data Safety Monitoring Board(DSMB) which is composed of more
      than 3 experts except principal investigator until the last visit. In each level 6 patients
      for investigational product and 2 patients for placebo will be allocated respectively in
      double blind manner.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference of ECG, vital sign and diagnostic test in JPI-289 group and placebo group</measure>
    <time_frame>-21d~9d</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference of concentration of JPI-289 in Plasma between JPI-289 group and placebo group</measure>
    <time_frame>0h~48h , 15 points</time_frame>
    <description>Blood
Urine 0h(pre-dose), 5min, 10min, 20min, 30min(before termination of infusion JPI-289), 45min, 1h, 2h, 4h, 8h, 12h, 24h, 48h</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Difference of PAR level in PBMC between JPI-289 group and placebo group</measure>
    <time_frame>0h(pre-dose)~48h, 6 points</time_frame>
    <description>-Blood 0h(pre-dose),1h, 4h, 7h, 24h, 48h</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>JPI-289</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each cohort, volunteers will be infused JPI-289 through I.V for 30 min.(6 volunteers per each cohort, total 7 cohort)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each cohort, volunteer will be infused placebo through I.V for 30 min.(2 volunteers per each cohort, total 7 cohort)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JPI-289</intervention_name>
    <description>PARP-1 inhibitor</description>
    <arm_group_label>JPI-289</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  19~55 years healthy male

          -  BMI measurement 20kg/m²~27kg/m²

          -  90 ≤ SBP＜140(mmHg) 60 ≤ DBP＜100(mmHg) 45 ≤ Pulse rate＜100(bpm)

          -  Signed the informed consent from to participate voluntarily and to comply with the
             trial requirements

          -  For a follow-up visit and during the study period, blood samples and availability

        Exclusion Criteria:

          -  History of clinically significant hepatic, gastrointestinal, pulmonary,
             musculoskeletal, endocrine, psychiatric, hematooncologic, cardiovascular (Specially
             asthma, obstructive pulmonary disease, peptic ulcer)

          -  History of skin disease of graft affecting absorption of the drug

          -  History of drug abuse

          -  Positive urine drug screening

          -  Administrated investigational product in a previous clinical trial within 60 days of
             the screening test

          -  Donated blood within 60 days prior to screening test
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HyeongSeok Lim, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>AIDS Malignancy Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Song-Pa Gu</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2013</study_first_submitted>
  <study_first_submitted_qc>November 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2013</study_first_posted>
  <last_update_submitted>June 23, 2016</last_update_submitted>
  <last_update_submitted_qc>June 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PARP-1 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

